RECENT Healthcare RESEARCH
AstraZeneca’s (AZN) stock value has fallen ~11.9% over the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~16.6% over the next 12 months.
Wall Street analysts’ lowest one-year target price for Boston Scientific (BSX) stock is $24, representing a -11.4% maximum downside risk potential for the next year.
Royalties paid to Ligand Pharmaceuticals (LGND) based on the sales of Amgen’s (AMGN) Kyprolis are a major revenue driver for the company. In 2Q17, LGND earned royalties of ~$222 million on Kyprolis’ sales.
Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of $5.6 billion.
On August 23, Stryker (SYK) announced a voluntary product recall of specific lots of oral care products that form part of the company’s Sage business unit.
As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x.
Around 80% of the analysts tracking Vertex Pharmaceuticals in August 2017 gave the stock some form of a “buy” rating.
Zimmer Biomet registered net sales of $1.95 billion, exceeding the analysts’ estimate, and saw year-over-year sales growth of around 1.1%.
In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.
On August 22, Medtronic (MDT) recorded $7.4 billion in revenues for fiscal 1Q18, falling short of Wall Street’s estimate of $7.5 billion. In this series, we’ll examine MDT’s outlook for fiscal 2Q18 and fiscal 2018.
Novartis missed the analysts’ estimate for 2Q17 revenues, reporting $12.24 billion and falling short of $12.27 billion, but surpassed the estimate for EPS.
In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.
Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”
Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.
Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.
Becton Dickinson (BDX) reported its 3Q17 earnings on August 3, 2017. The adjusted diluted EPS (earnings per share) came in at $2.46.
Medtronic (MDT) reported its fiscal 1Q18 earnings on August 22, 2017. In this series, we’ll look at its stock performance since then.
Of the 21 analysts tracking Merck in August 2017, three analysts recommended a “strong buy,” and ten analysts recommended a “buy.” Seven analysts recommended a “hold,” and one analyst recommended a “strong sell.”
Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.
Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.